Several different mutations collaborate with the fusion proteins in core-binding factor acute myeloid leukemia (CBF-AML) to induce leukemogenesis, but their prognostic significance remains unclear. We screened 354 predominantly younger (o60 years) adults with t(8;21) (n ¼ 199) or inv(16) (n ¼ 155) entered into UK MRC trials for KIT, FLT3 tyrosine kinase domain (FLT3 TKD ), N-RAS, K-RAS and c-CBL mutations and FLT3 internal tandem duplications (FLT3 ITD ) and assessed the impact of relative mutant level on outcome. Overall, 28% had KIT, 6% FLT3 ITD , 10% FLT3 TKD , 27% RAS and 6% CBL mutations. Mutant levels for all genes/loci were highly variable. KIT mutations were associated with a higher cumulative incidence of relapse but in multivariate analysis this was only significant for cases with a higher mutant level of 25% or greater (95% confidence interval (CI) ¼ 1.01-1.52, P ¼ 0.04). Similarly, only FLT3
INTRODUCTION
Investigation of molecular markers has an increasingly important role in the diagnosis and treatment of acute myeloid leukemia (AML), particularly where the markers are either strong prognostic indicators of clinical outcome, potential targets for therapy or suitable for minimal residual disease (MRD) evaluation. 1, 2 Mutations in the tyrosine kinase receptor c-KIT are predominantly associated with core-binding factor leukemias (CBF-AMLs), that is, t(8;21)(q22;q22) or inv(16)(p13q22)/ t(16;16)(p13;q22), hereafter called t (8;21) and inv (16) . CBF-AML is classified as favorable-risk disease because outcome is better than for other subtypes of AML. Nevertheless, in the analysis of 2644 patients aged 16-59 years treated in the United Kingdom Medical Research Council (MRC) trials, 10-year survival was still only 61% and 55% for t(8;21) and inv (16) patients, 3 although more recent use of the immunoconjugate gemtuzumab ozogamicin has improved this outlook. 4 Interest has therefore focused on determining whether the presence of c-KIT mutations can further refine risk stratification, particularly as they can be targeted using currently available kinase inhibitors. However, variable results have been reported for their prognostic significance. 5 For adult patients, c-KIT mutations in t(8;21) have generally been associated with a higher incidence of relapse, although studies differ as to whether overall survival (OS) is worse or not different, whereas in inv(16) many studies have found no difference for either relapse or OS, [6] [7] [8] [9] [10] [11] but a higher relapse rate has been reported, 12, 13 with worse OS in one of these cohorts. 12 These differences may relate to the small numbers of patients studied, the wide age range of some cohorts, often including pediatric patients where the impact of mutations may be different, 14, 15 and variations in the mutations investigated. The latter occur at several sites within the gene and may differ in their consequence. The most frequent are missense mutations in exon 17 encoding the activation loop in the tyrosine kinase domain (KIT TKD ), predominantly affecting asparate acid residue D816. Mutations in exon 8 are usually in-frame insertions or deletions that affect an extracellular domain of the receptor implicated in receptor dimerization (KIT ECD ). Although more common in gastrointestinal stromal tumors, missense mutations and inframe insertions/deletions have also been reported in exons 10 and 11 encoding the transmembrane and juxtamembrane domains (KIT TM þ JMD ), but have not been included in most studies examining prognosis. Relative mutant level has not been considered in studies to date, although this is an important feature when analyzing FLT3 mutations and may influence risk stratification. [16] [17] [18] [19] [20] [21] [22] Other mutations have also been reported in CBF-AML. These include FLT3 internal tandem duplications (FLT3 ITD ), FLT3
TKD mutations and a recently described novel FLT3 N676K missense mutation, codon 12, 13 and 61 mutations in N-RAS and K-RAS, and mutations in the RING-finger domain of c-CBL, an E3 ubiquitin ligase that negatively regulates activated receptor tyrosine kinases such as FLT3 and KIT. 6, 7, [9] [10] [11] 13, [23] [24] [25] [26] [27] However, there is little or no information available on the impact of these mutations in adult CBF-AML.
We therefore screened diagnostic samples from 354 predominantly younger adult patients with CBF-AML, treated on three consecutive UK MRC trials between 1988 and 2009, for c-KIT, FLT3, RAS and c-CBL mutations, determined relative mutant level, and examined the impact of a mutation and mutant level on prognosis, both overall and according to each cytogenetic subtype.
PATIENTS AND METHODS Patients
Diagnostic genomic (n ¼ 333) or complementary DNA (n ¼ 21) was available from 354 of 760 (47%) CBF-AML adults entered into the UK MRC AML10 (n ¼ 41), AML12 (n ¼ 134) or AML15 (n ¼ 179) trials. Paired DNA samples at disease relapse were available from 31 cases. Ethical approval for the trials and tissue collection for research was obtained from the Multi-Centre Research Committee of Wales. Informed consent was obtained in accordance with the Declaration of Helsinki. AML12 and AML15 are registered at http://www.controlled-trials.com under ISRCTN17833622 and ISRCTN17161961, respectively. Most patients (97%) had de novo AML. Median age at trial entry was 39 years, range 15-70; 95% were 59 or younger. Compared with the 406 excluded patients, investigated patients had slightly higher white cell count (WBC; P ¼ 0.09), but there were no significant differences in age, sex, presence of secondary disease, cytogenetic subtype, complete remission rate (CR) and OS (Supplementary Table 1 ).
Molecular analyses
Experimental details are given in the Data Supplement. c-KIT exons 17, 8 and 10 þ 11, N-RAS and K-RAS exons 2 and 3, and c-CBL exons 8 and 9 were screened by denaturing high-performance liquid chromatography of polymerase chain reaction (PCR) amplicons. Samples with abnormal chromatograms were sequenced. KIT
ECD , KIT
TM þ JMD and c-CBL mutations containing a size change were quantified by fragment analysis of fluorescently labeled PCR products, KIT TKD and RAS mutations by pyrosequencing. FLT3
ITD and FLT3 TKD mutation status and mutant level were determined as previously described. 18, 19 FLT3 N676K mutations were screened using BslI digestion of FLT3 exon 16 PCR products; samples with undigested bands indicative of mutant alleles were sequenced. For all loci, relative mutant level was expressed as a percentage of total alleles. Wherein more than one KIT or RAS mutation was identified, levels have been summed. Apparent mutants quantified as o5% were scored as wildtype (WT). A cutoff of 25% mutant was used for evaluation of mutant level, with a level of o25%, consistent with a heterozygous mutation in o50% of cells, scored as lower-level mutant (MUT LOW ), and X25% as higher-level mutant (MUT HIGH ). This arbitrary cutoff was based on the distribution of FLT3 ITD levels observed in our previous study, 19 and was used for all genes in preference to median level as these varied considerably between genes. Microsatellite analyzes were performed on paired diagnostic/relapse samples to confirm that they were from the same individual.
Therapy, clinical end points and statistical methods Details of the trial protocols have been published elsewhere. [28] [29] [30] Only 18 patients (5%) received a transplant in first CR. Clinical end points and statistical methods are defined in the Data Supplement. Median follow-up for surviving patients was 8.3 years (range, 1.7-22.1). Prognostic significance of mutant level in CBF-AML C Allen et al
RESULTS

Details
Nine patients had two different mutations in the same exon. The relative KIT mutant level was highly variable (median, 38%; range, 5-78%); 65% were KIT HIGH ( Figure 1a ). There was a significantly higher frequency of mutations in inv (16) Figure 1b ). They were significantly more frequent in t(8;21) than inv(16) (9% versus 3%, P ¼ 0.04). FLT3
TKD mutations were detected in 34 patients (10%), were more likely to be low level (median, 14%; range, 5-71%) and 38% were FLT3 TKD-HIGH ( Figure 1c ). They were significantly more frequent in inv(16) than t(8;21) (15% versus 6%, P ¼ 0.003). Only 4 of 276 patients analyzed (1%) had a FLT3 N676K mutation, all of them were inv(16) (3% of group).
RAS mutations were detected in 95 patients (RAS MUT , 27%), of which 62 (65%) were N-RAS, 30 (32%) K-RAS, and 3 (3%) both N-and K-RAS. Ten patients had more than one RAS mutation. The median RAS mutant level was 29% (range, 5-68%); 59% were RAS HIGH ( Figure 1d ). The frequency was significantly higher in inv(16) compared with t(8;21) (38% versus 18%, Po0.0001).
c-CBL mutations were detected in 22 patients (CBL MUT , 6%); of these 19 (86%) were in exon 8, two of which were missense mutations (C384Y, K389R) and 17 had size changes or splice site mutations that would be predicted to affect exon 8 splicing, and three (14%) were in exon 9 (N454D, Ins460D, 417P4RS). The median mutant level was 39% (range, 8-100%) and 73% were CBL HIGH ( Figure 1e ). There was no difference between the incidence in t(8;21) and inv(16) (7% versus 6%, P ¼ 0.8).
Overall, 116 patients (33%) had no detected mutations, a single gene was mutated in 201 (57%), and more than one gene in 37 (10%), the most frequent being co-incidence of c-KIT and FLT3 TKD mutations (n ¼ 11) and c-KIT and RAS mutations (n ¼ 10) (Supplementary Table 2 more frequent in KIT MUT cases (57% versus 30%, respectively, P ¼ 0.002), and RAS mutations were less frequent in patients with any additional chromosomal abnormality (54% for RAS MUT versus 73% for RAS WT , P ¼ 0.04). In inv (16) , no differences were observed in patient characteristics (Supplementary Table 4) . Similarly, although secondary chromosomal abnormalities were observed in 57 of 147 cases with available cytogenetics (39%), including 10% with trisomy 8 and 15% with trisomy 22, no association with genotype was observed.
Outcome stratified according to KIT genotype in the total cohort Details are given in Table 2 . KIT genotype had no impact on the remission rate. KIT MUT patients had a significantly higher cumulative incidence of relapse (CIR; 50% versus 35% at 10 years, hazard ratio (HR) ¼ 1.63, 95% confidence interval (CI) ¼ 1.10-2.42, P ¼ 0.01, log-rank test; Figure 2a) . The difference in OS was smaller and not statistically significant (52% versus 59%, HR ¼ 1.23, CI ¼ 0.86-1.77, P ¼ 0.3; Supplementary Figure 1A) . There was no evidence that outcome differed according to mutant location for either CIR (Figure 2b ) or OS (Supplementary Figure 1B) . Consequently, for subsequent analyses all mutations were considered together.
When Figure 1C ).
Outcome stratified according to FLT3, RAS and CBL genotypes in the total cohort FLT3 genotype had no impact on the rate of remission (Table 2) . Although relapse was highest in the FLT3 ITD-HIGH group, the difference was not significant (50%, 39% for FLT3
ITD-HIGH and FLT3
ITD-WT , respectively; HR ¼ 2.06, CI ¼ 0.65-6.57, P ¼ 0.2; Supplementary Figure 2A) . It was, however, a significant factor for worse OS, being lowest in the FLT3 ITD-HIGH cases (27%, 64% and 58%, respectively; Figure 3a) Figure 2D ) but, paradoxically, were significantly associated with improved outcome, and OS was significantly higher in the CBL HIGH cases (85% versus 44% for CBL HIGH and CBL WT , HR ¼ 0.45, CI ¼ 0.22-0.91, P ¼ 0.03; Figure 3d ). This was due to salvage of three of the five CBL HIGH cases that relapsed. A high CBL mutant level was a favorable factor for OS in multivariate analysis (HR ¼ 0.21, CI ¼ 0.05-0.85, P ¼ 0.02; Table 3 ).
As the impact on outcome for different mutations was highly variable and this would potentially confound the results for the non-mutated group when examining any specific gene/locus, outcome was compared for patients that were WT for all four mutations, excluding RAS, or MUT HIGH for just one of the four. Table 7) .
For the 155 inv (16) 
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Significance of the different genotypes in the multivariate analysis was not affected if presence or absence of secondary chromosomal abnormalities in the cytogenetic subgroups was included as an additional factor.
KIT genotype in paired diagnostic/relapse samples Paired relapse samples were available from 31 cases, 17 t(8;21) and 14 inv (16) , where microsatellite analysis confirmed that the samples were from the same individual. Overall, 18 cases (58%) : were KIT WT at both stages of disease (Supplementary Table 8 ). Seven cases (23%) were mutant at both time-points. Four had similar mutant levels at diagnosis and relapse, although one case with two mutations lost the minor mutant at relapse. One patient relapsed with a lower level of the same KIT JMD mutation, one had been scored as WT at diagnosis as the KIT TKD mutant detected was o5% but relapsed with the same mutation at a high level, and another with two mutants at diagnosis relapsed without the KIT JMD mutant and with a much higher level of the KIT TKD mutation. Mutation changes were detected in six patients. Five (16%) lost mutations at relapse, although in two cases the mutant level(s) were low at diagnosis, and a further case relapsed with a different KIT TKD mutation, both of them high level. In addition, two cases lost a FLT3 TKD-LOW mutant, two a CBL LOW and one a CBL HIGH mutant at relapse. There were too few cases to meaningfully determine whether the time to relapse differed in patients that retained or lost a mutation.
DISCUSSION
The fusion proteins that are the characteristic feature of CBF-AMLs are insufficient for leukemogenesis, and mouse models have demonstrated that cooperating mutations in tyrosine kinase receptors such as KIT and FLT3 can lead to disease initiation. [31] [32] [33] However, although many studies have investigated KIT mutations in CBF-AML, the results have been variable and their prognostic significance remains unclear. 5, 34 Some have suggested that currently there is no data supporting the use of KIT mutational status to guide therapy, 1 although guidelines published by the National Comprehensive Cancer Network recommend that patients with KIT mutations should be treated as intermediate-risk rather than favorable-risk and therefore considered for hematopoietic stem cell transplantation or clinical trials targeted toward the molecular abnormality. 35 Others have suggested that, although allogeneic hematopoietic stem cell transplantation has not been shown to improve outcome in t(8;21), 36 presence of a KIT mutation is sufficient to recommend human leukocyte antigen-identical sibling allogeneic hematopoietic stem cell transplantation if a suitable donor is available, with consideration given to a matched unrelated donor if not. 37 This study, which represents the largest analysis of CBF-AML in younger adult patients to date, suggests that the differences in outcome obtained in the various studies may reflect, at least in part, the heterogeneity in mutant level. Although the median KIT mutant level observed was 38%, consistent with a heterozygous mutation in the majority of cells, the range was very wide, 5-78%, and in multivariate analysis only presence of a KIT HIGH mutation, with at least half the cells in the total population carrying a mutation, was associated with a significantly increased relapse rate. Similar results were observed for FLT3 mutations; FLT3 ITD-HIGH mutations were associated with increased relapse and significantly worse OS, whereas FLT3
TKD-HIGH mutations were associated with lower relapse and a significantly better OS. These results are comparable to earlier reports that relative mutant level for both FLT3
ITD and FLT3 TKD mutations can influence clinical outcome, with a significant impact on outcome only observed in MUT HIGH cases in some reports. [16] [17] [18] [19] [20] [21] [22] Of note, the presence of a FLT3 TKD mutation was a powerful favorable prognostic factor in our study, which is consistent with our earlier results in unselected AML patients. 18 Other studies, however, have not found such a benefit, and the reasons for this are not clear. 13, 38, 39 A recent study reported that use of gemtuzumab ozogamicin in CBF-AML improved 5-year OS by 28%, 4 but it is not known if this is in all molecular subgroups. Such an analysis was not possible in this study, where only 39 patients received gemtuzumab ozogamicin, but is warranted when sufficient data on patients treated with this agent is available, and will need to include the impact of mutant levels. It has also been reported that MRD monitoring of the fusion transcripts is predictive of relapse. 30, 40 Only 69 patients in this study had also had MRD analysis, 30 34 with t(8;21) and 35 with inv (16) . Mutation status did not correlate with MRD results after course 1 of induction chemotherapy other than some suggestion of better MRD reduction in inv(16) cases with a FLT3 TKD (P ¼ 0.02), but this would require corroboration in a larger cohort. This suggests that gene mutation screening and MRD detection are complementary and both should be included in a prognostic model for risk stratification.
Another possible explanation for the variation in impact observed between studies is that KIT mutation location might influence clinical outcome. As the incidence of KIT ECD mutations differs significantly between the two cytogenetic subtypes, outcome would then be affected by the relative proportion of t(8;21) and inv (16) cases in the cohort studied. Furthermore, although most studies have screened for the tyrosine kinase and extracellular domains, few studies have examined the transmembrane/juxtamembrane domain where 11% of all mutations in the current cohort were detected. Mutations at all three locations have been associated with spontaneous in vitro dimerization, KIT autophosphorylation and factor-independent growth, but with differing efficiencies and effects on downstream signaling. [41] [42] [43] [44] In general, KIT ECD mutants have been reported as the most weakly activating and it has been suggested that they lead to ligand hypersensitivity, lowering the threshold of ligand concentration needed for activation, whereas KIT TKD mutants lead to ligandindependent activation. 41 Mouse models have also demonstrated differences in the potency of the various mutants, with a more TKD or CBL) or wild-type for all four. Cases with a mutation at more than one location were excluded.
aggressive phenotype induced for KIT TKD mutants compared with KIT ECD or KIT JMD mutants when co-expressed with the AML1-ETO fusion protein produced by the t(8;21) translocation. 32, 45 Whether this translates into any clinical difference has not been established. In the current cohort, we found no evidence that outcome differed according to mutation location, but these results should be treated with caution as once the patients were divided into subgroups, the numbers, particularly for the KIT TM þ JMD mutated group, were inevitably small and the power of the study limited.
Knowledge of which KIT mutation(s) are present will be important for the use of KIT inhibitors, as the response can be Prognostic significance of mutant level in CBF-AML C Allen et al mutation specific. Most mutants appear to be sensitive to dasatinib, but KIT TKD mutants affecting residue D816 (although not N822) are resistant to imatinib. 32, [41] [42] [43] 46 However, results of the analysis of paired presentation/relapse samples in this study have implications for the clinical use of KIT inhibitors as they demonstrated that nearly half of the KIT mutant-positive cases either lost or changed their mutation at relapse, including mutations from all three locations. These results indicate that, in at least some cases, presence of a KIT mutation may be acquired as a secondary mutation and that cells capable of generating a relapse do not carry this mutation. Similar results have been reported for FLT3 mutations. 47, 48 It is possible that these patients acquired other (unknown) mutations at relapse, a common feature of disease progression, 49 although none gained a FLT3 mutation.
Although RAS mutants have been shown to be leukemogenic in a mouse model, 50 and to enhance engraftment of AML1-ETO expressing CD34 þ cells in immunodeficient mice, 51 the lack of prognostic significance observed here for RAS mutations is consistent with other studies, both for unselected AML and CBF-AML. 9, 13, 52, 53 The impact of a CBL mutation has not been reported before in AML, although mutants lead to in vitro constitutive activation of the FLT3 pathway and are leukemogenic in mouse models. 24, 54, 55 Of interest, the favorable OS associated with a CBL HIGH mutation in this study was comparable to that observed for FLT3 TKD mutations rather than the adverse outcome for FLT3 ITD , which may indicate that CBL MUT cells have increased chemosensitivity. However, these results require confirmation in other cohorts because of the small number of mutant-positive cases, and a meta-analysis may be necessary. The significant difference in the incidence of mutations between the two cytogenetic subgroups, with a higher frequency of FLT3 ITD mutations in t(8;21) and KIT and FLT3 TKD mutations in inv (16) , was retained if only high-level mutants were considered. Although several studies have reported that the presence of different secondary cytogenetic abnormalities in the CBF-AML subgroups can be of prognostic significance, in particular with a better OS observed in inv(16) patients with trisomy 22, 3, 13, [56] [57] [58] there was no indication that presence of these abnormalities significantly impacted on the genotype results in multivariate analysis. Nevertheless, we found no evidence that mutant status could explain some of the differences observed between the two subgroups that have led to the suggestion that they should be considered as distinct entities. [56] [57] [58] Although the WBC was much higher overall in inv(16) than t(8;21) patients, there were no significant differences in either subgroup between KIT or FLT3 WT and mutated patients. Similarly, the impact of KIT or FLT3 mutations on outcome did not differ between the subgroups, and although a considerably higher relapse rate was observed overall in inv(16) compared with t(8;21) patients (54% versus 28%, Po0.0001), this difference could not be attributed to the presence of a KIT mutation. Indeed, the 10-year relapse rate for KIT WT patients was 25% in t(8;21) and 51% in inv (16) .
This study indicates that relative mutant level is important when assessing the prognostic impact of mutations in growth factor receptors and their downstream signaling pathways. The poorer prognosis associated with KIT and FLT3 ITD mutations and the better outcome associated with FLT3 TKD and CBL mutations in the CBF-AML cases studied appeared to be restricted to those cases with a mutant allele level of 425%. Quantification of allele levels would be necessary if knowledge of the presence of these mutations is to be used to modify therapy, such as by use of an allogeneic transplant in first CR, and it is likely that this information will become more readily available in the future with the introduction of next-generation sequencing platforms into routine diagnostic practice. In addition, the finding that KIT mutations are often absent in relapse suggests that the therapeutic value of KIT inhibitors is likely to be limited.
